Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review
Clinical Case Reports · 2026-07 · 14 (7)
DOI: 10.1002/ccr3.73006 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 22.06.2026. Verfasst von Yan Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo Beilun District Traditional Chinese Medicine Hospital Ningbo China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This report describes the case of a 73‐year‐old woman with advanced undifferentiated pleomorphic sarcoma (UPS) who was intolerant to chemotherapy. Following amputation, she received sintilimab plus anlotinib and achieved a partial response with 76.6% tumor reduction. This combination may be a potential option for chemotherapy‐ineligible advanced UPS, warranting further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ningbo Beilun District Traditional Chinese Medicine Hospital Ningbo China.
ORCID-Profile: Yan Chen
Zitieren
APA
Chen, Y., & Chu, R. (2026). Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review. Clinical Case Reports, 14(7). https://doi.org/10.1002/ccr3.73006
Vancouver
Chen Y, Chu R. Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review. Clinical Case Reports. 2026;14(7). doi:10.1002/ccr3.73006
BibTeX
@article{Chen2026,
author = {Chen, Yan and Chu, Ronghua},
title = {Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review},
journal = {Clinical Case Reports},
year = {2026},
volume = {14},
number = {7},
doi = {10.1002/ccr3.73006}
}
EUVIMED